Glioblastoma (GBM) is the most common malignant
primary brain tumor, and GBM patients have a poor overall prognosis. CDC20 expression is increased in a variety of
tumors and associated with
temozolomide (TMZ) resistance in
glioma cells.
Apcin specifically binds to CDC20 to inhibit APC/C-CDC20 interaction and exhibits antitumor properties. The purpose of this article was to assess whether
apcin inhibits
tumor growth in
glioma cell lines and increases the sensitivity of GBM to TMZ. In this study, a series of biochemical assays, such as Cell Counting Kit-8 (CCK-8), wound healing, apoptosis and colony formation assays, were performed to determine the antitumor properties of
apcin in
glioma cells. GBM cell apoptosis was detected by western blotting analysis of related
proteins.
Apcin increased the sensitivity of
glioma to TMZ, as confirmed by
CCK-8 and western blotting analysis. The results showed that
apcin significantly inhibited the proliferation of
glioma cells in a time- and dose-dependent manner. The migration decreased with increasing
apcin concentrations. Increased Bim expression indicated that
apcin promotes the apoptosis of
glioma cells. Furthermore,
apcin improved
glioma sensitivity to TMZ. The results showed that
apcin can effectively inhibit GBM growth and improve TMZ sensitivity.
Apcin has the potential to treat GBM and is expected to provide new ideas for individualized treatment.